Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Browsing: GLP-1 Receptor Agonists
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
Summary: In adults with chronic kidney disease and overweight or obesity but without diabetes, semaglutide 2.4 mg once weekly for…
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context The GLP-1…
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context Diabetic kidney…
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.